Mineralys Therapeutics In...
9.54
0.42 (4.61%)
At close: Jan 15, 2025, 10:00 AM

Mineralys Therapeutics Statistics

Share Statistics

Mineralys Therapeutics has 49.77M shares outstanding. The number of shares has increased by 0.28% in one year.

Shares Outstanding 49.77M
Shares Change (YoY) n/a
Shares Change (QoQ) 0.08%
Owned by Institutions (%) n/a
Shares Floating 23.55M
Failed to Deliver (FTD) Shares 1
FTD / Avg. Volume 0%

Short Selling Information

The latest short interest is 1.59M, so 3.19% of the outstanding shares have been sold short.

Short Interest 1.59M
Short % of Shares Out 3.19%
Short % of Float 6.74%
Short Ratio (days to cover) 9.24

Valuation Ratios

The PE ratio is -4.33 and the forward PE ratio is -3.86.

PE Ratio -4.33
Forward PE -3.86
PS Ratio 0
Forward PS 31.4
PB Ratio 1.29
P/FCF Ratio -3.83
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Mineralys Therapeutics Inc..

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 23.76, with a Debt / Equity ratio of 0.

Current Ratio 23.76
Quick Ratio 23.76
Debt / Equity 0
Total Debt / Capitalization 0
Cash Flow / Debt 0
Interest Coverage 0

Financial Efficiency

Return on equity (ROE) is -0.3% and return on capital (ROIC) is -35.1%.

Return on Equity (ROE) -0.3%
Return on Assets (ROA) -0.29%
Return on Capital (ROIC) -35.1%
Revenue Per Employee 0
Profits Per Employee -2.57M
Employee Count 28
Asset Turnover 0
Inventory Turnover 0

Taxes

Income Tax 0
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by 4.84% in the last 52 weeks. The beta is 2.46, so Mineralys Therapeutics 's price volatility has been higher than the market average.

Beta 2.46
52-Week Price Change 4.84%
50-Day Moving Average 12.56
200-Day Moving Average 12.54
Relative Strength Index (RSI) 27.81
Average Volume (20 Days) 205.78K

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -84.66M
Net Income -71.90M
EBITDA -84.66M
EBIT n/a
Earnings Per Share (EPS) -1.99
Full Income Statement

Balance Sheet

The company has 49.30M in cash and 0 in debt, giving a net cash position of 49.30M.

Cash & Cash Equivalents 49.30M
Total Debt 0
Net Cash 49.30M
Retained Earnings -124.71M
Total Assets 268.25M
Working Capital 236.41M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -81.17M and capital expenditures 0, giving a free cash flow of -81.17M.

Operating Cash Flow -81.17M
Capital Expenditures 0
Free Cash Flow -81.17M
FCF Per Share -2.24
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

MLYS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -21.87%
FCF Yield -17.92%
Dividend Details

Analyst Forecast

The average price target for MLYS is $30, which is 229.7% higher than the current price. The consensus rating is "Buy".

Price Target $30
Price Target Difference 229.7%
Analyst Consensus Buy
Analyst Count 2
Stock Forecasts

Scores

Altman Z-Score 9.94
Piotroski F-Score 1